Atossa Therapeutics (ATOS) said Tuesday that results from the ongoing phase 2 Evangeline trial showed that (Z)-endoxifen achieved target tissue concentrations and demonstrated substantial tumor suppression in premenopausal women with a type of breast cancer.
The drug candidate was generally well tolerated with manageable side effects, according to the company.
Based on findings from the pharmacokinetic run-in phase, the company plans to proceed with an amended protocol comparing (Z)-endoxifen 40 milligrams per day with ovarian function suppression to exemestane plus OFS.
Recruitment for this cohort will start in 2025, the company added.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。